Q

Quest Diagnostics

Operates nationwide clinical laboratory testing

Hospital Lab Manager

Full-Time
$76.7k - $138k+ $10,000 sign-on bonus
Expert
Bachelor's, Master's
Ponca City, OK, USA
In Person
Medical, Clinical & VeterinaryDiagnostics & Laboratory Professionals

About the job

Requirements
  • Five or more years of managerial experience in the laboratory industry.
  • Qualify under CLIA as a Medical Technologist or possess a bachelor’s degree in Medical Technology, Biology, or other related sciences, and qualify as a general laboratory supervisor under CLIA, 42 CFR 493.1461.
  • Hold Medical Laboratory Technician (MLT) certification from a nationally accredited certifying body.
  • Work independently in the field and be results-oriented.
  • Have strong project management, organizational, and analytical skills.
  • Manage multiple engagements concurrently.
  • Have strong interpersonal, presentation, and client interaction skills.
  • Have considerable knowledge of general laboratory services and testing requirements.
  • Demonstrate management and leadership skills.
  • Have excellent verbal and written communication skills.
  • Have knowledge of Lean Six Sigma principles and continuous improvement methodologies.
  • Have change management skills.
  • Be proficient with key PC software, including Word, Excel, and PowerPoint.
  • Have an advanced understanding of data analytics.
Responsibilities
  • Represent the Joint Venture in daily management of the individual hospital laboratory site, ensuring quality control standards and establishing, implementing, and maintaining standard operating procedures.
  • Collect and analyze data and prepare analyses and reports; lead daily hospital laboratory activities and represent the laboratory in hospital functional and leadership meetings.
  • Ensure laboratory technical staff perform effectively and meet hospital and Joint Venture expectations; maintain accountability for the accuracy and reliability of services provided by supervised lab departments.
  • Ensure policies and practices meet regulatory standards and requirements.
  • Serve as site manager for the DLO Lab Management team, providing hospital lab services according to the lab management agreement.
  • Participate in identifying, designing, developing, and implementing hospital laboratory management services for an individual hospital; participate in implementation plans, startup, and ongoing management for internal and external contracting requirements.
  • Coordinate internal and external resources to ensure timely completion of the lab management arrangement and ongoing contract success in accordance with client and company needs.
  • Train hospital management and/or staff, evaluate laboratory effectiveness and outcomes, and evaluate overall laboratory team performance.
  • Create a positive workplace for laboratory technical staff.
  • Maintain relationships and communications with the hospital client, sales, and DLO support services, with direct responsibility for DLO staff at the client hospital location.
  • Work with DLO Laboratory operations and functional partners, including procurement and logistics, to facilitate quality and timely delivery of laboratory testing services.
  • Provide regular, detailed status updates to DLO team members and hospital leadership, including monthly and quarterly reporting on productivity, quality, equipment, and process flows, and highlight issues and scope of services.
  • Ensure reference-testing samples are prepared for timely pickup; promptly share identified testing-performance issues with DLO, Quest, or the other reference laboratory and collaborate on resolution and improvement.
  • Act as an operations contact and liaison for hospital leadership and Joint Venture leadership to coordinate testing-service expectations.
  • Lead or participate in internal, client, and cross-functional meetings; participate in developing project plans, including laboratory space requirements and expansions of hospital testing services.
  • Collaborate with supply chain and procurement to maintain adequate, efficient inventory and use effective management and influencing skills to support successful implementation of services within scope.
  • Track department metric goals and actual performance and coordinate department activity to achieve goals.
  • Collaborate with the DLO Laboratory Director to establish and maintain the laboratory budget.
  • Initiate invoicing, complete capital-equipment requests, and perform other required financial activities, including managing labor productivity and cost per test.
Desired Qualifications
  • Prior managerial experience in a hospital setting.
  • A master’s degree in Business or Healthcare Administration.
  • Medical Laboratory Scientist (MLS) certification from a nationally accredited certifying body.
  • Demonstrated ability to lead or manage through supervisory or area-lead responsibilities.

About the company

Quest Diagnostics provides clinical laboratory testing and diagnostic services. It processes patient samples across a network of laboratories to run a broad menu of 3,000+ tests, including cancer diagnostics and anatomical pathology, and delivers interpretive reports through its medical staff. Tests are performed at its patient service centers, esoteric and rapid-response labs, and outpatient facilities, with results shared with clinicians via connected data systems. What sets Quest Diagnostics apart is its scale and scope: the world’s largest clinical lab network, the broadest test menu, a large team of MDs and PhDs for interpretation, and leadership in cancer diagnostics and pre-employment drug testing, plus extensive clinical trials testing. Its goal is to empower healthcare providers and patients with actionable diagnostic insights to identify, treat, and manage disease, inspire healthy behaviors, and improve health outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Secaucus, New Jersey

Founded

1967

Get referred to Quest Diagnostics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apple Health users will order Quest tests later in 2026, expanding direct-to-consumer reach.
  • Quest’s consumer-health business reached $250 million in 2025 and management targets 30% 2026 growth.
  • Quest will launch Roche pTau217 and its new multi-biomarker AD-Detect panel in Q4 2026.

What critics are saying

  • CMS cuts lab reimbursement up to 15% on January 1, 2027, hitting CMS revenue.
  • Quest faces NLRB case 14-CA-378210 over alleged discharge and coercive statements in St. Louis.
  • Repeated PAMA cuts and commoditized testing can squeeze Quest into a low-margin processing utility.

What makes Quest Diagnostics unique

  • Quest serves half of U.S. physicians and hospitals through 2,000 service centers.
  • Quest built a consumer-health platform with Apple Health, Oura, Hims & Hers, and Function Health.
  • Quest leads blood-based Alzheimer’s diagnostics with AD-Detect and Roche pTau217 launches in 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Company Match
  • Performance Bonus
  • Employee Stock Purchase Plan
  • Tuition Reimbursement
  • Wellness Program
  • Paid Vacation
  • Paid Holidays
  • Flexible Work Hours
  • 401(k) Retirement Plan

Company News

Yahoo Finance
Sep 22nd, 2026
Quest Diagnostics drops 5% as US cuts lab test reimbursement rates by 15%

Quest Diagnostics stock fell 5.1% on Tuesday after the Centers for Medicare and Medicaid Services announced it would cut reimbursement rates for lab work by up to 15%, effective 1 January 2027. CMS disclosed it has been paying approximately 16% more for lab tests than private insurers. The rate cuts could save taxpayers $1 billion annually but will reduce Quest's revenue. The company derives about 11% of its revenue from CMS reimbursement. If rates decrease by the full 15%, Quest's annual revenue would drop by 1.65%. Successive 15% annual reductions are possible through 2029, meaning a worst-case revenue reduction of slightly less than 5%. The company had warned in its SEC filing that Medicare and Medicaid rate changes posed risks to its business.

Citybiz
Sep 14th, 2026
Quanterix names yuri Fesko chief medical officer as diagnostics business expands.

Quanterix names yuri Fesko chief medical officer as diagnostics business expands. September 14, 2026 Dr. Yuri Fesko Quanterix Corporation has appointed Dr. Yuri Fesko chief medical officer, adding an experienced diagnostics executive as the company prepares for a broader market launch of its Lucent AD(R) Complete Alzheimer's disease test and advances regulatory work for its HD-X instrument. Fesko will provide medical and clinical leadership across the Nasdaq-listed precision biomarker company, working with its Diagnostics, Scientific, R&D, Regulatory and Commercial teams. He will be based at Quanterix's headquarters in Billerica, Massachusetts. The newly created role comes as Quanterix works to expand its diagnostics business and move more of its biomarker technologies into clinical applications. President and CEO Everett Cunningham said Fesko's background in clinical affairs and precision medicine will support both the commercialization of Lucent AD Complete and the company's planned IVD filing for HD-X. "As we prepare for the broader market launch of our Lucent AD Complete five biomarker test for Alzheimer's Disease, we welcome Dr. Yuri Fesko to Quanterix in an important new role to support our efforts to efficiently scale our expansion in diagnostics," Cunningham said. Fesko most recently served as chief medical officer at Quest Diagnostics, where he oversaw Medical Affairs, Clinical Development, Analytics and Public Health. He also served as the medical lead supporting the company's Quality and Regulatory functions and provided senior medical leadership for pathology and dermatopathology. His experience spans the development and implementation of precision medicine strategies in oncology, metabolic disease, neurology and consumer health. He has worked with health systems, pharmaceutical and biotechnology companies, and physician organizations to integrate precision diagnostics into clinical practice and clinical trials. Fesko also brings experience supporting FDA submissions, clinical development programs, companion diagnostic strategies and reimbursement planning. Those capabilities are relevant as Quanterix works to translate its biomarker research technologies into regulated diagnostic products and expand their use in clinical settings. One immediate priority is Lucent AD Complete, Quanterix's five-biomarker blood test for Alzheimer's disease. The company is preparing for a broader market launch of the test while simultaneously advancing the IVD regulatory filing for its HD-X instrument, making medical, regulatory and commercialization coordination a central part of Fesko's mandate. Cunningham said Fesko's ability to work across medicine, diagnostics, analytics and business strategy will support the company's efforts to build its Diagnostics business and broaden the clinical applications of its technology. Quanterix develops precision biomarker technologies designed to detect and quantify biological markers at very low concentrations. Its Simoa(R) platform provides high-sensitivity biomarker measurement in blood and other fluids, supporting applications across disease research, diagnostics and drug development. The company's technology portfolio has also expanded through its acquisition of Akoya Biosciences. Quanterix Spatial solutions provide high-plex quantitative protein analysis in tissue at single-cell resolution, adding spatial biology capabilities alongside its existing fluid biomarker technologies. Quanterix also operates Accelerator Laboratory services, providing researchers with additional capabilities for moving biomarker discoveries toward diagnostic applications. Together, those businesses give the company a platform spanning biomarker measurement, spatial analysis and laboratory services as it increases its focus on precision diagnostics. Fesko earned both his bachelor's degree and Doctor of Medicine from Case Western Reserve University and completed a fellowship at University Hospitals of Cleveland. He is board-certified in internal medicine, hematology and medical oncology. His appointment adds senior clinical leadership at a point when Quanterix is managing both product commercialization and regulatory execution. As the company expands beyond research applications, Fesko will help coordinate the medical evidence, regulatory strategy and clinical adoption required to move its biomarker technologies more broadly into diagnostic workflows.

PR Newswire
Sep 9th, 2026
Apple Health app users to order lab tests from Quest Diagnostics for $119

Apple Health app users in the United States will be able to purchase laboratory tests from Quest Diagnostics directly through the app later this year. Apple announced the update at its September event. Users can buy a Quest laboratory panel featuring over 50 biomarkers for $119. The panel assesses cardiometabolic health and organ function, including biometric readings for blood pressure, height, weight, and waist and hip circumferences. Customers can schedule blood draws and biometric readings at approximately 2,000 Quest patient service centres across the US. Results will appear in the Apple Health app shortly after testing. Quest collaborates with third-party providers to review test orders and discuss results at no additional charge.

Yahoo Finance
Sep 8th, 2026
Quest Diagnostics CEO sells 10,000 shares for $2.4M under pre-arranged trading plan

J.E. Davis, CEO and President of Quest Diagnostics, sold 10,000 shares of the diagnostic testing company for $2.4 million on 1 September 2026, according to an SEC Form 4 filing. The shares were sold at $242.72 each under a Rule 10b5-1 trading plan. Following the transaction, Davis retains 122,423 shares in the company, valued at $28.9 million. The sale occurred after Quest Diagnostics shares delivered a 32% total return over the preceding 12 months. Quest Diagnostics reported revenue of $11.6 billion and net income of $1.1 billion over the trailing twelve months. The company has a market capitalisation of $26.4 billion.

Ticker Report
Sep 5th, 2026
Man Group plc Makes New $495,000 Investment in Quest Diagnostics Incorporated $DGX

Man Group plc purchased a new position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,336 shares of the medical research company’s stock, valued at approximately $495,000. Several other hedge funds […]